Jörn M Schattenberg, Jeffrey V Lazarus, Philip N Newsome, Lawrence Serfaty, Alessio Aghemo, Salvador Augustin, Emmanuel Tsochatzis, Victor de Ledinghen, Elisabetta Bugianesi, Manuel Romero-Gomez, Heike Bantel, Stephen D Ryder, Jerome Boursier, Vincent Leroy, Javier Crespo, Laurent Castera, Lefteris Floros, Vincenzo Atella, Jorge Mestre-Ferrandiz, Rachel Elliott, Achim Kautz, Alice Morgan, Sally Hartmanis, Sharad Vasudevan, Lynne Pezzullo, Aldo Trylesinski, Sandrine Cure, Victoria Higgins, Vlad Ratziu
BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH) is a chronic disease that can progress to end-stage liver disease (ESLD). A large proportion of early-stage NASH patients remain undiagnosed compared to those with advanced fibrosis, who are more likely to receive disease management interventions. This study estimated the disease burden and economic impact of diagnosed NASH in the adult population of France, Germany, Italy, Spain and the United Kingdom (UK) in 2018. METHODS: The socioeconomic burden of diagnosed NASH was estimated using cost-of-illness methodology applying a prevalence approach to estimate the number of adults with NASH and the attributable economic and wellbeing costs...
February 15, 2021: Liver International: Official Journal of the International Association for the Study of the Liver